Patents Assigned to The United States of America as represented by the Secretary, Dept. of Health and Human Services
  • Publication number: 20240035006
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA or RNA-targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
    Type: Application
    Filed: November 14, 2022
    Publication date: February 1, 2024
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, University of Tokyo, The United States of America, as Represented by the Secretary Dept of Health and Human Services
    Inventors: Takashi Yamano, Hiroshi Nishimasu, Bernd Zetsche, Ian Slaymaker, Yinqing Li, Iana Fedorova, Kira Makarova, Linyi Gao, Eugene Koonin, Feng Zhang, Osamu Nureki
  • Publication number: 20240024479
    Abstract: Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express a thrombopoietin receptor, an erythropoietin receptor, or a chimeric polypeptide including an extracellular domain of a thrombopoietin receptor, a transmembrane domain, and an intracellular domain including an interleukin-2 receptor beta intracellular signaling domain. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.
    Type: Application
    Filed: October 3, 2023
    Publication date: January 25, 2024
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Richard W. Childs, David S.J. Allan
  • Patent number: 11878004
    Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: January 23, 2024
    Assignees: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services, Florida Stte University Research Foundation, Inc., The Trustees of the University of Pensylvania
    Inventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
  • Publication number: 20240018193
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Application
    Filed: September 11, 2023
    Publication date: January 18, 2024
    Applicant: The United State of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Publication number: 20240009236
    Abstract: Modified NK cells with reduced expression of CCR5 are provided. Methods of treating a subject with cancer with the modified NK cells are also provided. In some examples, the modified NK cells also have reduced expression of one or more of CCR1, CXCR6, and CD38, increased expression of one or more of CXCR4, CCR7, and CXCR3, and/or express a chimeric antigen receptor.
    Type: Application
    Filed: November 3, 2021
    Publication date: January 11, 2024
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Richard W. Childs, Emily R. Levy, Joseph Clara
  • Publication number: 20230406859
    Abstract: Compounds having general formula I or a pharmaceutically acceptable salt, N-oxide, or hydrate thereof are provided herein. Also provided are methods of making the compounds and methods of their use, including in treatment of cancer, autoimmune disorders, and viral infections.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 21, 2023
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: James Inglese, Ganesha Rai Bantukallu, Sandeep Rana, Laurence Lamy
  • Patent number: 11827690
    Abstract: The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 28, 2023
    Assignees: Novo Nordisk Inc., United State of America, As Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alan Thomas Remaley, Soumitra Shanker Ghosh, Madhav N. Devalaraja, Chih-Hung Lo, Denis O. Sviridov, Anna Wolska
  • Publication number: 20230341414
    Abstract: Provided are systems and methods for assessing the presence or risk of obstetrical complications, particularly those related to an angiogenic and anti-angiogenic imbalance. Also provided are methods of treating an angiogenic and anti-angiogenic imbalance with water-soluble statins, such as pravastatin.
    Type: Application
    Filed: May 10, 2023
    Publication date: October 26, 2023
    Applicants: Wayne State University, The United States of America as Represented by the Secretary., Dept. of Health and Human Services
    Inventors: Tinnakorn Chaiworapongsa, Roberto Romero, Sonia S. Hassan
  • Publication number: 20230330210
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Application
    Filed: May 8, 2023
    Publication date: October 19, 2023
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
  • Publication number: 20230295631
    Abstract: Disclosed herein are methods of treating a tumor in a subject, including administering to the subject one or more miRNA nucleic acids or variants (such as mimics or mimetics) thereof with altered expression in the tumor. Also disclosed herein are compositions including one or more miRNA nucleic acids. In some examples, the miRNA nucleic acids are modified miRNAs, for example, and miRNA nucleic acid including one or more modified nucleotides and/or a 5?-end and/or 3?-end modification. In particular examples, the modified miRNA nucleic acid is an miR-30a nucleic acid. Further disclosed herein are methods of diagnosing a subject as having a tumor with altered expression of one or more miRNA nucleic acids. In some embodiments, the methods include detecting expression of one or more miRNAs in a sample from the subject and comparing the expression in the sample from the subject to a control.
    Type: Application
    Filed: April 14, 2023
    Publication date: September 21, 2023
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, miRecule, Inc.
    Inventors: Anthony D. Saleh, Carter Van Waes, Zhong Chen, Hui Cheng
  • Publication number: 20230201298
    Abstract: Described herein is the design and construction of a class of lipoprotein targeting protease inhibitors. Small peptides with protease inhibitor activity are conjugated to hydrophobic, lipoprotein targeting molecules using, for instance, amine reactive chemistry. Methods of use of the resultant lipoprotein targeting protease inhibitor (antiprotease) molecules are also described. Also described is the production and use of protease inhibitor enriched HDL particles, as well as AlAT-peptide-enriched HDL particles, and their use in various therapeutic contexts.
    Type: Application
    Filed: June 13, 2022
    Publication date: June 29, 2023
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alan T. Remaley, Scott M. Gordon
  • Publication number: 20230190800
    Abstract: Chimeric antigen receptors including (a) an antigen binding domain; (b) a transmembrane domain; and (c) an intracellular domain comprising a first intracellular signaling domain from CD28 homolog (CD28H) and a second intracellular signaling domain are provided. In some examples, the second intracellular domain is from 2B4, TCR?, Fc?R1?, or DAP12. Chimeric antigen receptors including (a) an antigen binding domain; (b) a transmembrane domain; and (c) an intracellular domain comprising a first intracellular signaling domain from CD28H, a second intracellular signaling domain from 2B4, and a third intracellular signaling domain are also provided. In some examples, the third intracellular domain is from TCR?, Fc?R1?, or DAP12. Nucleic acid molecules encoding the CARs and expression vectors including the nucleic acids are also provided. Isolated cells (such as T cells or natural killer cells) expressing the CARs and methods of treating a subject with cancer with the isolated cells are provided.
    Type: Application
    Filed: March 26, 2020
    Publication date: June 22, 2023
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Eric O. Long, Xiaoxuan Zhuang
  • Patent number: 11654147
    Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: May 23, 2023
    Assignees: The Brigham and Women's Hospital, Inc., The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
  • Publication number: 20230089654
    Abstract: Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some embodiments, the NK cells or T cells express a thrombopoietin receptor or an erythropoietin receptor. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.
    Type: Application
    Filed: August 23, 2022
    Publication date: March 23, 2023
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Richard W. Childs, David S.J. Allan, Chantiya Chanswangphuwana
  • Patent number: 11542261
    Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: January 3, 2023
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Daniel T. Starczynowski, Craig J. Thomas, Garrett Rhyasen, Katelyn Melgar, Morgan MacKenzie Walker, Jian-kang Jiang
  • Publication number: 20220395569
    Abstract: Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, BKV serotype I (BKV-I), BKV serotype II (BKV-II), BKV serotype III (BKV-III) and/or BKV serotype IV (BKV-IV)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephropathy, BKV-associated hemorrhagic cystitis, or JC virus-associated progressive multifocal leukoencephalopathy; PML). Further disclosed are immunogenic compositions of use in the disclosed methods. Also disclosed are methods of selecting an organ transplant donor and/or recipient including detecting whether the prospective donor and/or recipient has BKV serotype-specific (such as BKV serotype IV-specific) neutralizing antibodies.
    Type: Application
    Filed: August 25, 2022
    Publication date: December 15, 2022
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Christopher B. Buck, Diana V. Pastrana
  • Patent number: 11505559
    Abstract: The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: November 22, 2022
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH, YALE UNIVERSITY
    Inventors: Shyh Ming Yang, David J. Maloney, Natalia Martinez, Adam Yasgar, Anton Simeonov, Vasilis Vasiliou
  • Publication number: 20220291094
    Abstract: Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid.
    Type: Application
    Filed: April 8, 2022
    Publication date: September 15, 2022
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Stephen M. Hewitt, Joon-Yong Chung, Candice D. Perry, Robert A. Star
  • Patent number: 11434268
    Abstract: The present invention provides variant VEGF polypeptides which have been altered in their C-terminal heparin binding region to lower their heparin binding affinity. These variants have been found to act as receptor antagonists for VEGF receptors and antagonize angiogenesis. These variants are useful to treat diseases characterized by pathological angiogenesis.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: September 6, 2022
    Assignee: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Donald P. Bottaro, Fabiola Cecchi
  • Publication number: 20220259317
    Abstract: An embodiment of the invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.
    Type: Application
    Filed: March 8, 2022
    Publication date: August 18, 2022
    Applicant: The United States of America,as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Christopher D. Chien, Terry J. Fry